We recently published a list of 10 Best Low Cost Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against other best low cost stocks to buy according to billionaires.
Markets are wobbling, and panic is becoming the headline. At times when stocks are tumbling, headlines are filled with forecasts that cause anxiety for investors. But it’s not new. The process has always been part of the stock market and each time, some specific factor becomes the trigger. In 2020, it was the COVID-19 pandemic. Right now, the new tariffs introduced by the U.S. President have become the panic-inducing trigger that has initiated a sharp sell-off across major U.S. indices.
According to CNBC, the significant composites in the U.S. have declined by nearly 5% after the new tariff announcement and the subsequent retaliation from major countries like China. Casual investors may perceive it as a red alert, but from the point of view of billionaire investors, it may signal a green light.
READ ALSO: 10 Best High-Risk Stocks to Buy According to Billionaires.
To them, it is not about timing the market but staying in it. Headlines may be screaming about the volatility of stocks in the U.S. market. Seasoned investors would still understand that sharp corrections sometimes open the door to long-term value. Because of the declining indices, some of the fundamentally sound stocks are available at cheap rates. Billionaire investors who prioritize value quietly build positions in low-cost assets as prices fall and fear takes over the investment environment. These billionaires are not moving impulsively but simply following their disciplined strategy, built from long-term thinking, which enables them to identify low-cost assets with strong fundamentals and room for growth.
At the same time, it is no surprise that more investors are unsure whether they should act or wait for some mythical perfect entry point because of the uncertainty prevailing in the market. However, this hesitation could prove costly. History has shown repeatedly that after a period of intense volatility, there follows a significant market gain.
Billionaires tend to understand this. They know that markets move in cycles, and short-term fear often fuels long-term wealth. Using their disciplined strategies, they use the rare chance to scoop up those stocks that trade at a low price despite their high potential.
It shows that low-cost stocks could provide investors with a satisfactory gain in the current market climate when chosen wisely. The stocks on our list are not just affordable. They have strong fundamentals and a potential upside that stand disproportionate to their current price tag. This is the primary reason they are incorporated into the portfolio of billionaire investors during the downturn.
When exploring our curated list of 10 best low-cost stocks to buy according to billionaires, we want the potential investors to remember that the goal is not to chase the market or guess the bottom. It is to think like those who are playing the long game. We are not imitating the billionaire investors, but only their mindset, which perceives the recent dip as an opportunity instead of a setback and employs a disciplined strategy to make an informed decision.
Our Methodology
We employed a few criteria when putting together our list of 10 best low-cost stocks to buy according to billionaires. We have defined low stocks as stocks with a price of less than $15. We have considered the upside potential of the stocks we have included in our list. Stocks with less than 20% upside potential are excluded from the list. It ensures that only those stocks with a high potential for earnings are presented to the investors. As part of the filtering process, we also excluded those stocks that did not have a Buy rating from analysts. These ratings increase the credibility of the picks in our article. All the data in the article was taken from financial databases and analyst reports, with all information updated as of April 6, 2025. The stocks were then ranked according to billionaires, taken from Insider Monkey’s exclusive database of billionaire stock holdings, as of Q4 2024.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Doctors in a lab coat attending to a patient receiving enzyme replacement therapies.
Amicus Therapeutics, Inc. (NASDAQ:FOLD)
No. of Billionaires: 11
Total Value of Billionaire Holdings: $0.34 Billion
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a biotechnology company specializing in rare and orphan diseases, particularly lysosomal storage disorders. The key products and pipeline candidates focus on precision therapies, such as Galafold for Fabry disease and AT-GAA for Pompe disease. Headquartered in Pennsylvania, the company competes with tough players like BioMarin and Sanofi. However, the patient-centric approach and innovative science in enzyme replacement and gene therapy offer a competitive edge for the company. Specifically, the targeted focus on high-unmet-need populations, supported by regulatory incentives for rare disease innovation, makes the company stand out among other competitors in the industry. It is one of the best cheap stocks to buy.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) draws support from 11 billionaires with $0.34 billion in holdings. 2024 has been a favorable year for the company, with full-year revenue reaching $528 million, a 32% increase compared to the previous year. The leading performer, Galafold, achieved revenue of $458 million, while Pombiliti and Opfolda reached over $70 million globally in 2024. The company’s guidance for 2025 involves a revenue growth of 17% to 24%. Contributors to this growth are a 10% to 15% projected growth in Galafold revenue and a 65% to 85% growth in Pombiliti + Opfolda.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) features 40 hedge fund portfolios at the end of Q4 2024, reflecting strong institutional support for the stock. Holding a Buy rating from analysts, FOLD has a remarkable upside of 126.67%, one of the highest on our list of valuable cheap stocks.
Overall, FOLD ranks 4th on our list of best low cost stocks to buy according to billionaires. While we acknowledge the potential for FOLD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than FOLD but trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
